参附注射液对严重创伤患者免疫功能调节的研究  

The effect of shenfu injection on immune function in severe trauma patients

作　　者：雷李美[1] 蓝翔[1] 考验[1] 郑浩[1] 潘杰[1] 黄丁丁[1] 

机构地区：[1]温州医科大学附属第六l临床医院丽水市人民医院急诊科全科医学科,浙江省丽水323000

出　　处：《中国基层医药》2015年第19期2928-2931,共4页Chinese Journal of Primary Medicine and Pharmacy

基　　金：基金项目：浙江省丽水市公益性技术应用项目（2012ZC037）

摘　　要：目的：探讨参附注射液对严重创伤患者免疫调节作用。方法使用随机数字表法将60例严重创伤患者随机分为对照组（30例）和参附治疗组（30例）。同期选取30例健康体检者为健康对照组。对照组给予常规诊治，参附治疗组则在常规救治的基础上早期加用参附注射液治疗。采用双抗体夹心酶联免疫吸附法（ELISA）测定患者治疗前、治疗后3 d 和7 d 的 CD ＋3、CD ＋4、CD ＋8细胞、单核细胞人白细胞 DR 抗原（HLA-DR）及血清白介素-1（IL-1）、IL-6水平。结果两治疗组血清 IL-1、IL-6水平均较健康对照组明显升高（f＝7．128，q ＝9．212、10．112，均 P ＜0．05）。治疗3 d 后，两治疗组 IL-1、IL-6均较治疗前明显升高（t ＝11．126、10．013，均 P ＜0．05）。治疗7 d 后，两治疗组 IL-1、IL-6水平明显下降（t ＝17．121、14．213，均 P ＜0．05）。接受治疗后，参附治疗组 IL-1、IL-6水平明显低于对照组（χ2＝4．113、10．117，均 P ＜0．05）。两组治疗前 CD ＋3、CD ＋4、CD ＋8和单核细胞 HLA-DR 表达及 CD ＋3／CD ＋8比值明显低于健康对照组（f＝11．071，q ＝10．229、12．032，均 P ＜0．05）。治疗3 d，参附治疗组 CD ＋3、CD ＋4、CD ＋8 T 淋巴细胞和单核细胞 HLA-DR 表达率均明显升高（t ＝10．013，P ＜0．05）。治疗7 d，两治疗组 CD ＋3、CD ＋4、CD ＋8 T 淋巴细胞和单核细胞 HLA-DR 表达率均明显升高（t ＝11．126、15．932，均 P ＜0．05）。治疗7 d，参附治疗组 CD ＋3、CD ＋4、CD ＋8 T 淋巴细胞和单核细胞 HLA-DR 表达率明显高于对照组（χ2＝3．771，P ＜0．05）。结论对严重创伤患者，参附注射液具有调节免疫功能作用，从而改善临床疗效。Objective To investigate the effect of shenfu injection on immune function in severe trauma patients.Methods 60 severe trauma patients were divided into the control group （n =30）and shefu group （n =30） by random number table.Other 30 cases were chosen as the health control group at the same phase.All patients were received conventional treatments,however,patients of the shenfu group were additionally received the shenfu injection treatment in the early stage.The CD ＋3 ,CD ＋4 ,CD ＋8 cell,human leukocyte antigen （HLA -DR）,interleukin -1（IL -1）,interleukin -6（IL -6）were detected on 3rd and 7th day by double -antibody sandwich enzyme -linked immu-nosorbent assay （ELISA）.Results Compared to the health control group,the IL -1,IL -6 in the control and shenfu group were significantly higher than the health control group（f=7.128,q =9.212,10.112,all P 〈0.05）.The IL -1and IL -6 in the control and shenfu group were significantly increased on 3rd day （t =11.126,10.013,all P 〈0.05）and decreased on 7th day（t =17.121,14.213,all P 〈0.05）.The IL -1 and IL -6 in shenfu group were sig-nificantly lower than that of the control group（χ2 =4.113,10.117,all P 〈0.05）.The CD ＋3 ,CD ＋4 ,CD ＋8 ,HLA -DR and CD ＋3 /CD ＋8 rate in the control and shenfu group were significantly lower than the health control group（f=11.071, q =10.229,12.032,all P 〈0.05）.On 3rd day,the CD ＋3 ,CD ＋4 ,CD ＋8 ,HLA -DR and CD ＋3 /CD ＋8 rate in shenfu group were significantly increased（t =10.013,P 〈0.05）.On 7th day,CD ＋3 ,CD ＋4 ,CD ＋8 ,HLA -DR and CD ＋3 /CD ＋8 rate in the control and shenfu group were both increased（t =11.126,15.932,all P 〈0.05）.And the CD ＋3 ,CD ＋4 ,CD ＋8 ,HLA -DR and CD ＋3 /CD ＋8 rate in shenfu group were significantly higher than the control group（χ2 =3.771,P 〈0.05）.Conclusion Shenfu injection can regulate immune function in severe trauma and improve clinical treatment.

关 键 词：创伤和损伤 免疫调节 参附注射液 

分 类 号：R641[医药卫生—外科学]